Q32 Bio (QTTB) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing antibody-based biologics for autoimmune and inflammatory diseases, targeting both adaptive and innate immune pathways.

• Lead candidate bempikibart (ADX-914) is a monoclonal antibody targeting IL-7Ra, with completed Phase 2a trials in alopecia areata and atopic dermatitis; focus is now on alopecia areata.

• ADX-097, a Phase 2 asset, is a tissue-targeted complement inhibitor; development deprioritized following a corporate restructuring in February 2025.

• Additional early-stage assets and discovery efforts are ongoing in complement inhibition.

Financial performance and metrics

• As of March 27, 2025, public float was approximately $22.2 million, with 12,197,615 shares outstanding and 5,223,283 held by affiliates.

• Market value of public float is below $75 million, qualifying as a smaller reporting company.

Use of proceeds and capital allocation

• Net proceeds from any securities sale will be used for general corporate purposes, including working capital, research, clinical development, commercial efforts, administrative expenses, acquisitions, and other business opportunities.

• Management retains broad discretion over capital allocation.